{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Comparator+2&page=35",
    "query": {
      "intervention": "Active Comparator 2",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 941,
    "total_pages": 95,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Comparator+2&page=36&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Comparator+2&page=34&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T04:57:28.315Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04104685",
      "title": "A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "FCD105",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "3% Minocycline Foam",
          "type": "DRUG"
        },
        {
          "name": "0.3% Adapalene Foam",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Foam",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vyne Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 446,
      "start_date": "2019-09-18",
      "completion_date": "2020-03-03",
      "has_results": false,
      "last_update_posted_date": "2021-02-05",
      "last_synced_at": "2026-10-27T04:57:28.315Z",
      "location_count": 35,
      "location_summary": "Bryant, Arkansas • Rogers, Arkansas • Encino, California + 32 more",
      "locations": [
        {
          "city": "Bryant",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04104685"
    },
    {
      "nct_id": "NCT06151574",
      "title": "Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Cancer, Non-squamous, Non-small Cell"
      ],
      "interventions": [
        {
          "name": "zongertinib",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 428,
      "start_date": "2024-02-09",
      "completion_date": "2028-01-28",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-27T04:57:28.315Z",
      "location_count": 22,
      "location_summary": "Huntsville, Alabama • Bullhead City, Arizona • Beverly Hills, California + 19 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Bullhead City",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06151574"
    },
    {
      "nct_id": "NCT04611152",
      "title": "A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "KSI-301",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Kodiak Sciences Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 460,
      "start_date": "2020-09-30",
      "completion_date": "2023-08-31",
      "has_results": true,
      "last_update_posted_date": "2024-08-22",
      "last_synced_at": "2026-10-27T04:57:28.315Z",
      "location_count": 48,
      "location_summary": "La Jolla, California • Redlands, California • Santa Maria, California + 44 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04611152"
    },
    {
      "nct_id": "NCT07612449",
      "title": "Percepta for Cognitive Optimization",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mild Cognitive Impairment (MCI)",
        "Memory"
      ],
      "interventions": [
        {
          "name": "Percepta",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Cerebrum DAO Association",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 154,
      "start_date": "2026-09-14",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-27T04:57:28.315Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07612449"
    },
    {
      "nct_id": "NCT06409819",
      "title": "Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urinary Tract Infection, Recurrent"
      ],
      "interventions": [
        {
          "name": "phage therapy",
          "type": "DRUG"
        },
        {
          "name": "control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 32,
      "start_date": "2025-06-15",
      "completion_date": "2027-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-10-27T04:57:28.315Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06409819"
    },
    {
      "nct_id": "NCT02426190",
      "title": "Knee Arthroplasty Rehabilitation Outcomes Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Total Knee Arthroplasty",
        "Rehabilitation"
      ],
      "interventions": [
        {
          "name": "Anti-gravity treadmill",
          "type": "OTHER"
        },
        {
          "name": "PENS - neuro-muscular stimulation",
          "type": "OTHER"
        },
        {
          "name": "Anti-gravity treadmill & PENS - neuro-muscular stimulation",
          "type": "OTHER"
        },
        {
          "name": "Recumbent or Nu-step bike",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "MedStar National Rehabilitation Network",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 386,
      "start_date": "2014-10",
      "completion_date": "2017-12-31",
      "has_results": false,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-10-27T04:57:28.315Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02426190"
    },
    {
      "nct_id": "NCT04558918",
      "title": "Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
      ],
      "interventions": [
        {
          "name": "LNP023",
          "type": "DRUG"
        },
        {
          "name": "Eculizumab",
          "type": "DRUG"
        },
        {
          "name": "Ravulizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2021-01-25",
      "completion_date": "2023-03-06",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-10-27T04:57:28.315Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Orange, California • Augusta, Georgia + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04558918"
    },
    {
      "nct_id": "NCT04793685",
      "title": "Prazosin for Alcohol Use Disorder With Withdrawal Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Withdrawal"
      ],
      "interventions": [
        {
          "name": "Prazosin",
          "type": "DRUG"
        },
        {
          "name": "12-Step Facilitation with Relapse Prevention and Contingency Management",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 152,
      "start_date": "2021-07-01",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-27T04:57:28.315Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04793685"
    },
    {
      "nct_id": "NCT05668754",
      "title": "Study of SDX in Patients With Idiopathic Hypersomnia (IH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Hypersomnia"
      ],
      "interventions": [
        {
          "name": "Serdexmethylphenidate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Zevra Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2022-12-28",
      "completion_date": "2024-03-21",
      "has_results": true,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-10-27T04:57:28.315Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Daphne, Alabama • Guntersville, Alabama + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05668754"
    },
    {
      "nct_id": "NCT00865761",
      "title": "A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Alprazolam 3 mg Extended Release Tablets, single dose",
          "type": "DRUG"
        },
        {
          "name": "XANAX XR® 3 mg tablets, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2005-09",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2010-08-17",
      "last_synced_at": "2026-10-27T04:57:28.315Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00865761"
    }
  ]
}